Log in

Relevant bibliographies by topics / Sofosbuvir And Daclatasvir / Journal articles

To see the other types of publications on this topic, follow the link: Sofosbuvir And Daclatasvir.

Journal articles on the topic 'Sofosbuvir And Daclatasvir'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Sofosbuvir And Daclatasvir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sacramento, Carolina Q., Natalia Fintelman-Rodrigues, Jairo R. Temerozo, et al. "In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19." Journal of Antimicrobial Chemotherapy 76, no. 7 (2021): 1874–85. http://dx.doi.org/10.1093/jac/dkab072.

Full text

Abstract:

Abstract Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. Methods SARS-CoV-2-infected

APA, Harvard, Vancouver, ISO, and other styles

2

Chakravarthy, V. Ashok, Sailaja Bbv, and Praveen Kumar A. "METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM." Asian Journal of Pharmaceutical and Clinical Research 9, no. 9 (2016): 61. http://dx.doi.org/10.22159/ajpcr.2016.v9s3.14616.

Full text

Abstract:

ABSTRACTObjective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitativeestimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir in its active pharmaceutical ingredient (API) form.Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir isbased on measurement of absorption at a wavelength maximum (λmax) of 317 and 261 nm using methanol as solvent.Results: The method was validated in terms of specificity, precision, linearity, a

APA, Harvard, Vancouver, ISO, and other styles

3

C. Damle, Mrinalini, and Nivedita B. Pawar. "STABILITY INDICATING HPLC METHOD FOR SOFOSBUVIR AND DACLATASVIR IN COMBINATION." Indian Drugs 59, no. 10 (2022): 74–79. http://dx.doi.org/10.53879/id.59.10.12506.

Full text

Abstract:

Direct acting fixed dose combination of sofosbuvir and daclatasvir to treat the viral hepatitis C disease is available in the market. So, a precise and robust stability indicating HPLC method for sofosbuvir and daclatasvir was developed. The SunQ C18 column (250 x 4.6 mm) was used for chromatographic separation with mobile phase consisting of 0.03 mM potassium dihydrogen phosphate buffer (pH 7): ACN (50: 50V/V). Optimised method satisfies the system suitability parameters with good resolution with 4.9 min Rt of sofosbuvir and 7.6 min Rt of daclatasvir. The method was validated as per ICH guide

APA, Harvard, Vancouver, ISO, and other styles

4

Ahmad Ather, Ch Adnan, Mariyam Nawaz, Sohail Bashir Sulehria, Saadia Chaudary, Zara Mehmood, and Maria Rehman. ""TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"." Journal of Akhtar Saeed Medical & Dental College 05, no. 02 (2023): 90–96. https://doi.org/10.51127/jamdcv5i2oa05.

Full text

Abstract:

Background:To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin.Material and Methods:Total 180 patients meeting inclusion criteria were enrolled in the studyfromDepartment of Medicine, Government Teaching Hospital Shahdara, Lahore.This randomized controlled trial was conducted fromMarch 25, 2021,to September 24, 2021.Treatment naive cases were given tablet sofosbuvir & daclatasvir for 12 weeks. Treatment-experienced and naive with cirrhosis were given ribavirin based on their body weight along with sofosbuvir and daclatasv

APA, Harvard, Vancouver, ISO, and other styles

5

Mobarak, Sara, Mehdi Salasi, Ahmad Hormati, et al. "Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)." Journal of Antimicrobial Chemotherapy 77, no. 3 (2021): 758–66. http://dx.doi.org/10.1093/jac/dkab433.

Full text

Abstract:

Abstract Background The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. Methods This was a placebo-controlled, double-blind, randomized clinical trial in adults hospitalized with COVID-19 at 19 hospitals in Iran. Patients were randomized to oral sofosbuvir/daclatasvir 400/60 mg once-daily or placebo in addition to standar

APA, Harvard, Vancouver, ISO, and other styles

6

Eslami, Gholamali, Sajedeh Mousaviasl, Esmat Radmanesh, et al. "The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19." Journal of Antimicrobial Chemotherapy 75, no. 11 (2020): 3366–72. http://dx.doi.org/10.1093/jac/dkaa331.

Full text

Abstract:

Abstract Objectives Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19. Methods Patients with a positive nasopharyngeal swab for SARS-CoV-2 on RT–PCR or bilateral multi-lobar ground-glass opacity on their chest CT and signs of severe COVID-19 were included. Subjects were divided into two arms with one arm receiving

APA, Harvard, Vancouver, ISO, and other styles

7

Hessel, Marleen H. M., Adam F. Cohen, and Robert Rissmann. "Sofosbuvir and daclatasvir." British Journal of Clinical Pharmacology 82, no. 3 (2016): 878–79. http://dx.doi.org/10.1111/bcp.13011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Abdelaty, Lamiaa N., Ahmed A. Elnaggar, Amira A. Said, and Raghda R. S. Hussein. "Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients." Current Drug Safety 15, no. 1 (2020): 53–60. http://dx.doi.org/10.2174/1574886314666191001151314.

Full text

Abstract:

Background: Chronic Hepatitis C (CHC) is a common progressive healthcare challenge that leads to liver cirrhosis, liver failure, and hepatocellular carcinoma. The optimum therapy was a combination of pegylated interferon and ribavirin, which was associated with moderate response and severe side effects. Sofosbuvir revolutionized CHC treatment, especially in combination with other antiviral agents. Objective: The aim of this study was to compare and evaluate the safety and efficacy of sofosbuvir/ daclatasvir versus sofosbuvir/ledipasvir for the treatment of non-cirrhotic naïve patients with chr

APA, Harvard, Vancouver, ISO, and other styles

9

Damle, Mrinalini, and Nivedita Pawar. "Stability Indicating HPTLC Method for Sofosbuvir and Daclatasvir in Combination." International Journal of Pharmaceutical Sciences and Nanotechnology 13, no. 6 (2020): 5234–42. http://dx.doi.org/10.37285/ijpsn.2020.13.6.8.

Full text

Abstract:

Direct acting antiviral agents represent the major advance in treatment of hepatitis C virus (HCV) infection. Daclatasvir with sofosbuvir that are co-administrated once per day oral dose has been reported to achieve a high rate of virological response in patients with HCV genotype 1, 2 or 3. So, the basic objective of a research involved development and validation of stability indicating HPTLC Method for simultaneous estimation of Sofosbuvir and Daclatasvir available in market in the form of combination tablet. Samples were applied on HPTLC aluminium plates precoated with silica gel 60 F254 (2

APA, Harvard, Vancouver, ISO, and other styles

10

Sangani, Monika, and Nirav V. Patel. "STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF SOFOSBUVIR AND DACLATASVIR IN TABLET DOSAGE FORM." Indian Drugs 59, no. 11 (2022): 73–80. http://dx.doi.org/10.53879/id.59.11.13047.

Full text

Abstract:

New stability indicating RP-HPLC method for the simultaneous estimation of sofosbuvir and daclatasvir in its pharmaceutical dosage form was developed and validated. Column used was PhenomenexC18 (150mm x 4.6mm, 5µ) with mobile phase water and acetonitrile (50:50 V/V) in isocratic mode. Flow rate of mobile phase 1.0mL min-1 and column oven temperature were maintained at 30o C. Sofosbuvir and daclatasvir were detected at a wavelength 230nm. The retention times for sofosbuvir and daclatasvir were found to be 3.06 min and 4.76 min, respectively. Validation of the method was done according to ICH g

APA, Harvard, Vancouver, ISO, and other styles

11

Badkhal, Amol, Prachi Verma, Sandip Umare, Vishal Patond, Dhirendra Sanghai, and Priti Chincholkar. "RP-HPLC Method for the Simultaneous Determination of Sofosbuvir and Daclatasvir in Pure and Pharmaceutical Dosage Forms." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 14, no. 04 (2023): 1158–64. http://dx.doi.org/10.25258/ijpqa.14.4.51.

Full text

Abstract:

Daclatasvir and sofosbuvir in pure and medicinal dosage forms can be determined quickly and easily using a reversed-phase high-performance liquid chromatography (RP-HPLC) technique. An accurate, reproducible method was developed and validated. The mobile phase contained a mixture of 90% methanol:10% water (0.05% OPA). UV estimation was done with a flow rate of 0.7 mL/min and wavelength of 275 nm. The temperature was 30°C. Sofosbuvir stays in the body for 3.361 minutes and daclatasvir for 5.745 minutes. A quantitative study of commercial dosage forms went well with this method, which was made a

APA, Harvard, Vancouver, ISO, and other styles

12

Arif, Mohammad, Shah Zaman, Amir Zaman Khan, and Riaz Nasim. "Efficacy of Sofosbuvir and Daclatasvir in the Treatment of Chronic Hepatits C Viral Infection." Pakistan Journal of Medical and Health Sciences 15, no. 12 (2021): 3164–66. http://dx.doi.org/10.53350/pjmhs2115123164.

Full text

Abstract:

Aim: To know the efficacy of combined therapy with sofosbuvir and daclatasvir, in patients suffering from chronic hepatitis C viral infection in Khyber Pakhtunkhwa. Study Design: Descriptive case series study. Place and duration of study: Department of Gastroenterology, Hayatabad Medical Complex, Peshawar, Pakistan, from 1stOctober 2017 to 28th February 2019. Methodology: Ninety eight patients were suffering from chronic hepatitis C infection enrolled. All patients were treated with sofosbuvir 400 mg and daclatasvir 60 mg daily for a period of three to six months. Ribavirin was added to the tr

APA, Harvard, Vancouver, ISO, and other styles

13

Ahmed, Tanveer, Omer Hassaan Aftab Ahmad, Muhammad Bilal, Sher Alam, Shirjeel Zaheer, and Zaid Gul. "Comparison of Efficacy of Sofosbuvir & Daclatasvir with Sofosbuvir and Velpatasvir in Achieving SVR in Patients of Chronic Hepatitis C with Genotype 3." Pakistan Journal of Medical and Health Sciences 16, no. 4 (2022): 1155–58. http://dx.doi.org/10.53350/pjmhs221641155.

Full text

Abstract:

Background and Aim: Hepatitis C virus of chronic nature has been appreciated globally to be a major source of hepatic carcinomas and other abnormalities associated with liver function. The epidemiological data on the prevalence of the Hepatitis C virus shows a trend of 71 million people being affected by the disease globally with an annual mortality rate of 3.5 to 5 million death. Pakistan showed a prevalence of up to 8.2% which is among the most common incidents in countries. Since genotype 3 is the most common variant in Pakistan there remains a literature gap that evaluates the effectivenes

APA, Harvard, Vancouver, ISO, and other styles

14

SHULPEKOVA, Y. O., N. V. SHULPEKOVA, M. C. SEMENISTAYA, A. A. USANOVA, and C. S. PAVLOV. "TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR." Medical Council, no. 4 (May 26, 2017): 36–41. http://dx.doi.org/10.21518/2079-701x-2017-4-36-41.

Full text

Abstract:

The purpose of the review is to evaluate the efficacy and safety of using pangenotypic combination «of Sofosbuvir/Daclatasvir» — the direct action antiviral drugs in the treatment of chronic HCV infection at different stages of liver damage.Main provisions: Sofosbuvir is the antisense nucleotide, inhibiting RNA-dependent RNA-polymerase NS5B, this drug has earned a reputation as one of the strongest anti-replication drugs, including when there is interferon resistance. Daclatasvir is a powerful non-nucleotide inhibitor of NS5А protein, catalyzing formation of replicative complexes. Both compone

APA, Harvard, Vancouver, ISO, and other styles

15

Benzil, Dudekula1* Dr.C.Ramachandraiah2 Dr.N.Devanna3. "ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND DACLATASVIR DRUG PRODUCT BY RP-HPLC METHOD." INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH 07, no. 09 (2017): 480–87. https://doi.org/10.5281/zenodo.1036476.

Full text

Abstract:

Analytical method was developed for the estimation of Sofosbuvir and Daclatasvir drug substance by liquid chromatography. The chromatographic separation was achieved on C18 column (XTerra RP18 150*4.6, 5um) at ambient temperature .The separation achieved employing a mobile phase consists of 0.1%v/v Trifluoro acetic acid in water: Acetonitrile (60:40). The flow rate was 1.0 ml/ minute and ultra violet detector at 275nm. The average retention time for Sofosbuvir and Daclatasvir found to be 2.09 and 3.50 min. The proposed method was validated for selectivity, precision, linearity and accuracy. Al

APA, Harvard, Vancouver, ISO, and other styles

16

Muzammil, Muhammad, Muhammad Tahir, Nadeem Ullah, Malik Muhammad Arif, Talha Rasheeq, and Muhammad Mumtaz Ather. "Comparison of Efficacy of Daily Sofosbuvir and Declatasvir with Alternate Day Sofosbuvir and Declatasvir in Hepatitis C Patients on Hemodialysis in Pakistani Population." Pakistan Journal of Medical and Health Sciences 16, no. 8 (2022): 264–66. http://dx.doi.org/10.53350/pjmhs22168264.

Full text

Abstract:

Objective: compare the efficacy of daily Sofosbuvir plus Declatasvir with alternate day Sofosbuvir and Declatasvir in HCV patients on hemodialysis. Study design: Randomized clinical trial Place and duration: department of general medicine Nishtar hospital, Multan from March 2020 to March 2021 in one year duration. Methodology: A total of 260 patients were enrolled in study and divided into two groups (1 and 2) by convenient sampling technique. Non probability consecutive sampling technique was used. Group 1 treated with Sofosbuvir plus Declatasvir daily and group 2 was treated with alternate S

APA, Harvard, Vancouver, ISO, and other styles

17

Essawy, Aya, Mai Mehrez, Sara M. Shaheen, Hassan El Garem, and Nagwa A. Sabri. "New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin." F1000Research 10 (May 30, 2022): 1105. http://dx.doi.org/10.12688/f1000research.73076.2.

Full text

Abstract:

Background: Several studies have resulted in controversial data about the recurrence or new incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C who were treated with direct-acting antivirals (DAAs). Aim: This observational study aimed to assess the occurrence rate of HCC in patients who developed a sustained virological response (SVR).. METHOD: A six-month prospective study was done at the National Hepatology and Tropical Medicine Research Institute [NHTMRI] in Cairo, Egypt on 150 chronic hepatitis C (CHC) patients treated with sofosbuvir and daclatasvir with or without ri

APA, Harvard, Vancouver, ISO, and other styles

18

Ather, Hafiz Mughees, Idrees Shani, Muhammad Aamer, Arfan Mahmood, and Nazir Ahmad. "Efficacy of dacaltasvir and sofosbuvir combination therapy in chronic HCV population in private clinic set up." Professional Medical Journal 27, no. 07 (2020): 1323–27. http://dx.doi.org/10.29309/tpmj/2020.27.08.486.

Full text

Abstract:

All- oral antiviral therapy for chronic hepatitis C is standard of care in 2018. Daclatasvir and Sofosbuvir combination therapy was approved in 2015 by EASL. Generics are also available since 2016. Objectives: We evaluated efficacy of Daclatasvir and Sofosbuvir based therapy in cirrhotic and non-cirrhotic patients. Study Design: Retrospective Observational Study. Setting: Athar Medical Center Muslim Town, Sargodha Road, Faisalabad. Period: One Year Dec 2017 to Dec 2018. Material & Methods: 151 patients were treated with Daclatasvir 60 mg daily and Sofosbuvir 400 mg daily combination therap

APA, Harvard, Vancouver, ISO, and other styles

19

Essawy, Aya, Mai Mehrez, Sara M. Shaheen, Hassan El Garem, and Nagwa Sabri. "New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin." F1000Research 10 (November 2, 2021): 1105. http://dx.doi.org/10.12688/f1000research.73076.1.

Full text

Abstract:

Background: Several studies have resulted in controversial data about the recurrence or new incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C who were treated with direct-acting antivirals (DAAs). Aim: This observational study aimed to assess the occurrence rate of HCC in patients who developed a sustained virological response (SVR).. METHOD: A six-month prospective study was done at the National Hepatology and Tropical Medicine Research Institute [NHTMRI] in Cairo, Egypt on 150 chronic hepatitis C (CHC) patients treated with sofosbuvir and daclatasvir with or without ri

APA, Harvard, Vancouver, ISO, and other styles

20

Essawy, Aya, Mai Mehrez, Sara M. Shaheen, Hassan El Garem, and Nagwa A. Sabri. "New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin." F1000Research 10 (July 3, 2024): 1105. http://dx.doi.org/10.12688/f1000research.73076.3.

Full text

Abstract:

Background: Several studies have resulted in controversial data about the recurrence or new incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C who were treated with direct-acting antivirals (DAAs). Aim: This observational study aimed to assess the occurrence rate of HCC in patients who developed a sustained virological response (SVR). METHOD: A six-month prospective study was done at the National Hepatology and Tropical Medicine Research Institute [NHTMRI] in Cairo, Egypt on 150 chronic hepatitis C (CHC) patients treated with sofosbuvir and daclatasvir with or without rib

APA, Harvard, Vancouver, ISO, and other styles

21

Abbaspour Kasgari, Hamideh, Siavash Moradi, Amir Mohammad Shabani, et al. "Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial." Journal of Antimicrobial Chemotherapy 75, no. 11 (2020): 3373–78. http://dx.doi.org/10.1093/jac/dkaa332.

Full text

Abstract:

Abstract Background New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19. Methods This was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran. Patients were randomly assigned to 400 mg sofosbuvir, 60 mg daclatasvir and 1200 mg ribavirin (intervention group) or to st

APA, Harvard, Vancouver, ISO, and other styles

22

Dr., Adeela Ilyas Dr. Ayesha Bajwa Dr. Filza Karim. "A COMPARATIVE RESEARCH TO ASCERTAIN VIROLOGIC REACTION IN CHRONIC HEPATITIS C VIRUS (HCV) PATIENTS BY TWO DIFFERENT TREATMENT OPTIONS." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 12 (2018): 17173–79. https://doi.org/10.5281/zenodo.2528523.

Full text

Abstract:

<strong><em>Objective:</em></strong><em> This study was designed to ascertain the virologic reactions in patients of chronic hepatitis C, cured by means of sofosbuvir and daclatasvir versus sofosbuvir and ribavirin.</em> <strong><em>Methodology:</em></strong><em> It was a probable comparative research study which was administered in Allied Hospital, Faisalabad from February to October 2017. With either gender, chronic hepatitis C virus detected patients with age ranges from 18 to 60 years having detectable HCV RNA through PCR were select for study. Based on treatment, patients were divided int

APA, Harvard, Vancouver, ISO, and other styles

23

Soliman, Elwy M. K., Hisham A. A. Morsy, Ashraf M. M. Othman, and Ahmed M. Mady. "Predictor factors of sustained virological response in patients with chronic hepatitis C treated with current direct-acting antiviral drugs." Tropical Journal of Pharmaceutical Research 19, no. 9 (2020): 2015–20. http://dx.doi.org/10.4314/tjpr.v19i9.30.

Full text

Abstract:

Purpose: To assess the efficacy and predictors of treatment response of chronic hepatitis C genotype 4 Egyptian patients with sofosbuvir and daclatasvir, with or without ribavirin.Methods: This prospective study enrolled 200 patients with chronic hepatitis C virus (HCV) genotype 4 infection who received sofosbuvir plus daclatasvir for 12 weeks, with the addition of ribavirin for treating cirrhotic patients. Immunological parameters such as natural killer (NK) cell percentage, phenotype, and serum C-X-C motif chemokine 10 (CXCL10) were evaluated prior to treatment and at the end of the treatmen

APA, Harvard, Vancouver, ISO, and other styles

24

Ullah, Zabih, Sultan Zeb Khan, Hassam Lodhi, Hafizullah Khan, Rania Hidayat, and Moiz Ahmed. "Efficacy of Sofosbuvir and Daclatasvir in Achieving the End Treatment Response and Sustained Viral Response in Patients infected with Hepatitis C Virus Genotype 3." Pakistan Armed Forces Medical Journal 72, no. 3 (2022): 1074–77. http://dx.doi.org/10.51253/pafmj.v72i3.4470.

Full text

Abstract:

Objective: To ascertain the efficacy of sofosbuvir combined with daclatasvir against hepatitis C genotype 3 infection. Study Design: Prospective longitudinal study. Place and Duration of Study: Ayub Teaching Hospital, Abbottabad, Pakistan, from Nov 2018 to Jan 2020. Methodology: About 262 patients were treated during the study. Patients with symptoms associated with liver failure, including ascites, uncontrolled bleeding, encephalopathy and other comorbidities, were excluded from the study. Patients with diagnosed hepatitis C genotype 3 infection were given daclatasvir and so

APA, Harvard, Vancouver, ISO, and other styles

25

Sharma, Sourabh, Debabrata Mukherjee, Ranjith K. Nair, Bhaskar Datt, and Ananth Rao. "Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients." Journal of Transplantation 2018 (2018): 1–10. http://dx.doi.org/10.1155/2018/7579689.

Full text

Abstract:

Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral agents in RTRs.Methods. This prospective observational study was conducted at Army Hospital Research & Referral, Delhi, from June 2016 to May 2017. Forty-five HCV infected RTRs with stable graft function were included.Results. Median time between renal transplantation and the start of anti-HCV therapy was 36 months (1–120 months). The majo

APA, Harvard, Vancouver, ISO, and other styles

26

Kareem Ali Maher, Reda Biomy Bastawesy, Mahmoud Mohammed Youssef, Wael Anwar Haseeb, and Mariam Salah Zaghloul. "Evaluation of left ventricular function after sofosbuvir and daclatasvir regimen for chronic hepatitis C." Journal of the Pakistan Medical Association 73, no. 4 (2023): S131—S135. http://dx.doi.org/10.47391/jpma.egy-s4-27.

Full text

Abstract:

Objectives: To assess left ventricular functions by echocardiography after 12 weeks of sofosbuvir-daclatasvir combination therapy.Method: The prospective cohort study was conducted from December 2019 to December 2021 at Kafrelsheikh University Hospital, Egypt, and comprised adult patients of either gender who had been referred to the Cardiovascular Department for cardiac evaluation and were found to be eligible for sofosbuvir-daclatasvir combination therapy. The patients were classified into five groups according to cardiovascular risk factors. Group 1 had no risk factors; Group 2 had many ris

APA, Harvard, Vancouver, ISO, and other styles

27

Rahmani, Parisa, Fatemeh Farahmand, and Ghobad Heidari. "Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy." Journal of Child Science 12, no. 01 (2022): e79-e82. http://dx.doi.org/10.1055/s-0042-1751269.

Full text

Abstract:

AbstractThe present study includes a case report of a 9-year-old boy who came to our center with jaundice, elevated liver enzymes, and palpable liver. He was treated with ursodeoxycholic acid, but no improvement in symptoms was seen. Reverse transcription polymerase chain reaction and liver biopsy were positive for hepatitis C virus. He was treated with daclatasvir/sofosbuvir for 3 months. Daclatasvir/sofosbuvir might be effective against the treatment of hepatitis in children, with no report of remission and minimal side effects.

APA, Harvard, Vancouver, ISO, and other styles

28

Jonathan, Andreas, Rudi Wisaksana, and Nenny Agustanti. "Decreased in Liver Fibrosis in Patients with HCV/HIV Coinfection After Treatment with Sofosbuvir/Daclatasvir." Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy 20, no. 2 (2020): 87–95. http://dx.doi.org/10.24871/202201987-95.

Full text

Abstract:

Background: Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) co-infection increases the progression of liver fibrosis to advanced liver disease and death. The aim of this study is to determine whether decreased of liver fibrosis occur in HCV/HIV coinfection patients after therapy with Sofosbuvir/daclatasvir. Method: This study used a quasi-experimental study design without a control group. The study subjects were HCV/HIV coinfection patients who received Sofosbuvir / daclatasvir therapy in the Gastroentero-Hepatology Clinic of Dr. Hasan Sadikin Hospital. In this study measurement of

APA, Harvard, Vancouver, ISO, and other styles

29

Nadeem Islam, Shirin Aamir, Aleena Hussain Rana, Syed Mohsin Naveed, and Wasim Ahmad. "Response of Daclatasvir and Sofosbuvir in Treatment-Naïve, HCV Genotype 3, Non-Cirrhotic Pakistani Population: 1 Year Follow-Up Experience." Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University 19, no. 2 (2023): 147–51. http://dx.doi.org/10.48036/apims.v19i2.838.

Full text

Abstract:

using daclatasvir and sofosbuvir in treatment-naive, non-cirrhotic HCV genotype 3 Pakistani population. Methodology: From January 2017 to February 2019, HCV patients who met the inclusion criteria were included in this open-label, non-randomized, uncontrolled observational trial at HBS General Hospital in Islamabad. A 12-week course of oral daclatasvir and sofosbuvir therapy was administered to each participant. Each patient got 400mg of sofosbuvir and 60mg of daclatasvir. Treatment outcomes included sustained virological response (SVR12 and SVR24), rapid virological response (RVR), and end-of

APA, Harvard, Vancouver, ISO, and other styles

30

Mostafi, M., M. Jabin, Z. Chowdhury, et al. "The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection." Ukrainian Journal of Nephrology and Dialysis, no. 2(66) (April 16, 2020): 3–8. http://dx.doi.org/10.31450/ukrjnd.2(66).2020.01.

Full text

Abstract:

Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to their use in developing countries. Aim. This study aimed to evaluate the efficacy of low dose Sofosbuvir along with Daclatasvir in the management of HCV infection in end-stage renal disease (ESRD) patients. Methods. A total of 82 HCV positive patients on ESRD were included in this study. The patients were observed for six months without

APA, Harvard, Vancouver, ISO, and other styles

31

Saleem, Komal, Amjad Ali, Shazia Rafique, Noshaba Rani, and Braira Wahid. "Successful retreatment of HCV relapse patient with 4 weeks long sofsobuvir, ribavirin, and daclatasvir combination: Case Series." BioScientific Review 2, no. 3 (2020): 17–25. http://dx.doi.org/10.32350/bsr/2020/23/1119.

Full text

Abstract:

Hepatitis-C virus (HCV) is an enveloped RNA virus that currently infects more than 180 million people, worldwide. Interferon therapy was previously used as a standard therapy for HCV. Now it has been replaced with an interferon-free therapy or the direct acting antiviral (DAA) drug therapy. Although the DAA drug therapy is a potent strategy which has an excellent efficacy against the HCV infection with a majority of patients achieving sustained virological response (SVR), we report here three patients who experienced relapse after a 6-month long DAA drug therapy. The patients experienced relap

APA, Harvard, Vancouver, ISO, and other styles

32

Godela, Ramreddy, and Sowjanya G. "Concurrent Determination of Daclatasvir and Sofosbuvir in Pure Binary Mixture and Their Combined Film Coated Tablets by a Simple Stability Indicating RP-HPLC Method." Research Journal of Pharmacy and Technology, November 30, 2021, 5913–18. http://dx.doi.org/10.52711/0974-360x.2021.01028.

Full text

Abstract:

A trouble-free, simple, specific and highly sensitive stability indicating phase HPLC method was developed for concurrent assessment of Daclatasvir and Sofosbuvir in pure and in their combined tablet formulation. An effectual separation was accomplished by using XDB Phenyl (250 x 4.6mm, 5µ,100 A0) column, mobile phase composition of Acetonitrile: buffer(0.1%v/v Trifluoroaceticacid in water) (50:50 v/v) and isocratic elution at a flow rate of 1ml/min and detection wavelength of 275nm. The extreme stress conditions like hydrolysis with acid and base, peroxide oxidation, thermal decomposition wer

APA, Harvard, Vancouver, ISO, and other styles

33

"Daclatasvir/sofosbuvir/ledipasvir/sofosbuvir." Reactions Weekly 1839, no. 1 (2021): 101. http://dx.doi.org/10.1007/s40278-021-89939-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

"Daclatasvir/sofosbuvir/ledipasvir/sofosbuvir." Reactions Weekly 1763, no. 1 (2019): 124. http://dx.doi.org/10.1007/s40278-019-65216-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Yamana, Anil Vikas, and Chandra Sekhar Kothapalli Bonnoth. "Validated Method development for estimation of Sofosbuvir and Daclatasvir in bulk and their dosage form by using RP-HPLC." Research Journal of Pharmacy and Technology, June 28, 2022, 2447–50. http://dx.doi.org/10.52711/0974-360x.2022.00408.

Full text

Abstract:

A simple, Accurate, precise method was developed for the simultaneous estimation of the Sofosbuvir and Daclatasvir in Tablet dosage form. Chromatogram was run through Standard Ascentis C18 150 x 4.6mm, 5m. Mobile phase containing Acetonitrile: Water taken in the ratio 60:40 was pumped through column at a flow rate of 0.7ml/min. Temperature was maintained at 30°C. Optimized wavelength selected was 279nm. Retention time of Sofosbuvir and Daclatasvir were found to be 2.198 min and 2.765 min. %RSD of the Sofosbuvir and Daclatasvir were and found to be 0.4 and 0.3 respectively. %Recovery was obtain

APA, Harvard, Vancouver, ISO, and other styles

36

"Daclatasvir/sofosbuvir." Reactions Weekly 1837, no. 1 (2021): 195. http://dx.doi.org/10.1007/s40278-021-88794-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Daclatasvir/sofosbuvir." Reactions Weekly 1879, no. 1 (2021): 119. http://dx.doi.org/10.1007/s40278-021-04603-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Daclatasvir/sofosbuvir." Reactions Weekly 1689, no. 1 (2018): 72. http://dx.doi.org/10.1007/s40278-018-41941-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Daclatasvir/sofosbuvir." Reactions Weekly 1692, no. 1 (2018): 125. http://dx.doi.org/10.1007/s40278-018-42653-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Daclatasvir/sofosbuvir." Reactions Weekly 1713, no. 1 (2018): 120. http://dx.doi.org/10.1007/s40278-018-49954-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Daclatasvir/sofosbuvir." Reactions Weekly 1713, no. 1 (2018): 121. http://dx.doi.org/10.1007/s40278-018-49955-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Daclatasvir/sofosbuvir." Reactions Weekly 1722, no. 1 (2018): 123. http://dx.doi.org/10.1007/s40278-018-52452-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Daclatasvir/sofosbuvir." Reactions Weekly 1633, no. 1 (2017): 251. http://dx.doi.org/10.1007/s40278-017-24520-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Daclatasvir/sofosbuvir." Reactions Weekly 1640, no. 1 (2017): 119. http://dx.doi.org/10.1007/s40278-017-26672-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Daclatasvir/sofosbuvir." Reactions Weekly 1640, no. 1 (2017): 120. http://dx.doi.org/10.1007/s40278-017-26673-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Daclatasvir/sofosbuvir." Reactions Weekly 1641, no. 1 (2017): 103. http://dx.doi.org/10.1007/s40278-017-27017-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Daclatasvir/sofosbuvir." Reactions Weekly 1647, no. 1 (2017): 106. http://dx.doi.org/10.1007/s40278-017-28798-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Daclatasvir/sofosbuvir." Reactions Weekly 1681, no. 1 (2017): 126. http://dx.doi.org/10.1007/s40278-017-39402-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Daclatasvir/sofosbuvir." Reactions Weekly 1683, no. 1 (2018): 240. http://dx.doi.org/10.1007/s40278-018-40177-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Daclatasvir/sofosbuvir." Reactions Weekly 1833, no. 1 (2020): 145. http://dx.doi.org/10.1007/s40278-020-86963-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!